Sol-Gel Technologies (SLGL)
NASDAQ:SLGL
Want to see SLGL full AI Analyst Report?
Top Page
Sol-Gel Technologies
(NASDAQ:SLGL)
Select Model
Select Model
Rating:51Neutral
Price Target:
$64.00
▼(-13.36% Downside)
Action:Reiterated
Date:03/21/26
The score is driven primarily by improving financial trajectory (strong 2025 revenue rebound, positive operating/free cash flow, and very low debt) tempered by continued losses and equity erosion. Technicals are mixed/neutral, and valuation is pressured by a negative P/E and no dividend yield.
Positive Factors
Low leverage / conservative balance sheet
Very low absolute debt and historically low leverage give Sol‑Gel durable financial flexibility to fund R&D and commercialization without heavy interest burdens. This reduces near-term insolvency risk and supports strategic optionality while the company pursues its dermatology pipeline.
Negative Factors
Cumulative equity erosion from sustained losses
A materially smaller equity base over several years reduces the company’s capital buffer and financial resilience. Continued erosion limits borrowing capacity, increases vulnerability to adverse shocks, and raises the probability of dilutive financings if profitability and cash generation are not reliably restored.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / conservative balance sheet
Very low absolute debt and historically low leverage give Sol‑Gel durable financial flexibility to fund R&D and commercialization without heavy interest burdens. This reduces near-term insolvency risk and supports strategic optionality while the company pursues its dermatology pipeline.
Read all positive factors
Sol-Gel Technologies (SLGL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$213.43M
Dividend YieldN/A
Average Volume (3M)16.66K
Price to Earnings (P/E)―
Beta (1Y)1.66
Revenue Growth68.04%
EPS Growth42.09%
CountryUS
Employees34
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.54
Shares Outstanding3,268,991
10 Day Avg. Volume26,975
30 Day Avg. Volume16,656
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)5.15
Price to Sales (P/S)6.06
P/FCF Ratio426.90
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue27.73
Enterprise Value/Gross Profit-18.07
Enterprise Value/Ebitda-11.07
Forecast
1Y Price Target
$184.00Price Target Upside149.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-6.81
Revenue Forecast (FY)$5.30M
Sol-Gel Technologies Business Overview & Revenue Model
Company Description
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead ...
How the Company Makes Money
Sol-Gel makes money primarily from commercializing its prescription dermatology products and from partnering with other pharmaceutical companies to market and sell those products. Key revenue streams include: (1) product sales revenue from prescri...
Sol-Gel Technologies Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
72
Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.56M | 19.39M | 11.54M | 1.55M | 3.88M | 31.27M |
| Gross Profit | -10.07M | 19.28M | 11.30M | -21.99M | -8.80M | 10.89M |
| EBITDA | -16.43M | -7.48M | -10.35M | -28.96M | -15.68M | 3.84M |
| Net Income | -14.91M | -6.13M | -10.58M | -27.24M | -14.92M | 3.22M |
Balance Sheet | ||||||
| Total Assets | 42.01M | 29.92M | 35.85M | 45.29M | 46.63M | 69.19M |
| Cash, Cash Equivalents and Short-Term Investments | 30.47M | 24.00M | 23.93M | 38.00M | 33.63M | 43.24M |
| Total Debt | 1.39M | 991.00K | 1.31M | 1.65M | 772.00K | 1.59M |
| Total Liabilities | 7.10M | 7.11M | 7.00M | 6.64M | 4.42M | 13.60M |
| Stockholders Equity | 34.90M | 22.81M | 28.85M | 38.64M | 42.21M | 55.59M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 275.00K | -13.89M | -17.86M | -9.65M | -7.83M |
| Operating Cash Flow | 0.00 | 322.00K | -13.89M | -17.73M | -9.48M | -7.69M |
| Investing Cash Flow | 0.00 | -8.58M | 26.69M | -9.74M | 1.70M | 19.87M |
| Financing Cash Flow | 0.00 | 6.00K | 0.00 | 21.81M | 15.00K | 837.00K |
Sol-Gel Technologies Technical Analysis
Neutral
73.87
Price Trends
74.21
Negative
71.59
Negative
51.96
Positive
Market Momentum
-2.16
Positive
46.48
Neutral
25.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLGL, the sentiment is Neutral. The current price of 73.87 is above the 20-day moving average (MA) of 71.20, below the 50-day MA of 74.21, and above the 200-day MA of 51.96, indicating a neutral trend. The MACD of -2.16 indicates Positive momentum. The RSI at 46.48 is Neutral, neither overbought nor oversold. The STOCH value of 25.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SLGL.
Sol-Gel Technologies Risk Analysis
Sol-Gel Technologies disclosed 72 risk factors in its most recent earnings report. Sol-Gel Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sol-Gel Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $199.88M | -6.60 | 380.80% | ― | -49.28% | 57.96% | |
54 Neutral | $446.07M | ― | -22.51% | ― | 1199.64% | 30.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $213.43M | -19.16 | -24.29% | ― | 68.04% | 42.09% | |
50 Neutral | $473.12M | ― | -60.73% | ― | -78.29% | 54.16% | |
46 Neutral | $48.56M | -0.55 | -51.23% | ― | -50.66% | -9.30% | |
45 Neutral | $314.06M | -0.63 | 309.79% | ― | -35.61% | -68.92% |
* Healthcare Sector Average
SLGL
Sol-Gel Technologies
68.31
60.63
788.87%
IMDX
Insight Molecular Diagnostics
5.88
2.44
70.93%
OVID
Ovid Therapeutics
2.44
2.15
753.15%
STTK
Shattuck Labs
6.09
5.09
509.00%
SRZN
Surrozen
27.09
18.95
232.80%
MGX
Metagenomi, Inc.
1.31
-0.36
-21.56%
Sol-Gel Technologies Corporate Events
Sol-Gel Technologies Prices $33.1 Million Oversubscribed Equity Offering to Advance SGT-610
Mar 24, 2026
On March 23, 2026, Sol-Gel Technologies entered into an underwriting agreement for an oversubscribed underwritten offering of 459,112 ordinary shares at $72.00 per share, for expected gross proceeds of about $33.1 million, with closing anticipated...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.